Revenue
No reported data
Seaport Therapeutics, Inc. (SPTX)
Price—Loading quote
Net income
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Research & development | — | $0 |
| Operating income | −$87.3M | −$52.4M |
| Net income | −$74.9M | −$46.9M |
| Diluted EPSper diluted share | -$31.54 | -$49.72 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 | HOMBACH ROBERT J.Director | BuyCommon Stock · indirect | 13.0K | $18.14 | $235.8K | 13.0K |
| May 4, 2026Form 4 | ARCH Venture Partners XII, L.P. +6TenPercentOwner | BuyCommon Stock · indirect | 1.10M | $18.00 | $19.80M | 6.29M |